Apolipoprotein(a) [apo(a)] / apo(a)-apoB100 interaction

Class

Oral small-molecule Lp(a) inhibitor

Pathway

Blocks the binding between apo(a) and apoB-100, inhibiting assembly of Lp(a) particles and lowering circulating Lp(a) levels

Apolipoprotein(a), or apo(a), is a distinctive protein component of lipoprotein(a), commonly abbreviated Lp(a), an LDL-like particle circulating in blood. Lp(a) forms when apo(a) attaches to apolipoprotein B-100 (apoB-100), the structural protein of LDL particles, first through a reversible binding step and then a stable covalent bond. Elevated Lp(a) is largely determined by genetics rather than diet or lifestyle, and it is an independent risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease, acting through mechanisms that include cholesterol deposition in arterial walls and pro-inflammatory and pro-thrombotic properties linked to apo(a)'s structural resemblance to plasminogen, a clotting-pathway protein. Because Lp(a) levels are not effectively lowered by conventional lipid-lowering approaches such as statins, there has been long-standing interest in mechanisms that directly interrupt Lp(a) formation or clearance. This particular approach targets the initial binding step between apo(a) and apoB-100, aiming to prevent Lp(a) particle assembly before it enters circulation. As an oral small molecule rather than an injectable biologic, this mechanism represents an alternative route to lowering Lp(a), relevant to research on reducing residual cardiovascular risk that persists despite adequate control of LDL cholesterol.